Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valproate In The Spotlight As EMA Releases Date For First Ever Public Hearing

Executive Summary

The European Medicines Agency has released the date for its public hearing on valproate in which EU citizens will for the first time be given a voice in evaluating the safety of medicines on the market.

You may also be interested in...

Parties Vie For Place At EMA’s First Ever Public Hearing On Medicines Safety

The first ever public hearing on the safety of marketed medicines being organized by the European Medicines Agency has drawn a “very positive” response from the members of the public who have applied to attend the event on Sept. 26. The agency is now shortlisting an appropriate mix of speakers and observers.

Waiting For The Perfect Case: Why EMA Has Yet To Hold A Public Drug Safety Hearing

The European Medicines Agency has yet to use the power it has to hold public hearings on marketed medicines that raise safety concerns. It says it will do so only when the time is right.

EMA to go extra mile to facilitate joint safety study for valproate

In the course of its mandate to help companies carry out joint post-authorization safety studies under the EU pharmacovigilance legislation, the European Medicines Agency is planning to organize a teleconference/webinar for a new study concerning the anti-epileptic drug valproate so that interested companies may be introduced to each other and have the opportunity to interact and raise questions.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts